Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst(Yale Cancer Center), Jean‐Charles Soria(Institut Gustave Roussy), Marcin Kowanetz, Gregg Fine, Omid Hamid, Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott Gettinger(Yale Cancer Center), Holbrook E. Kohrt, Leora Horn, Donald P. Lawrence(Massachusetts General Hospital), Sandra Rost, Maya K. Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, Daniel S. Chen, F. Stephen Hodi

Nature

November 25, 2014

10.1038/nature14011

Cited by 5,253

Abstract

Related Papers

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al.|European Journal of Cancer|2008|29.3k

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi, Steven O’Day, David F. McDermott et al.|New England Journal of Medicine|2010|15.1k

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al.|New England Journal of Medicine|2012|8k

Oncology Meets Immunology: The Cancer-Immunity Cycle

Daniel S. Chen, Ira Mellman|Immunity|2013|6.9k

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Haidong Dong, Scott E. Strome, Diva R. Salomão et al.|Nature Medicine|2002|5k